ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,041.41
-0.09%
US Tech 100
20,613.20
0.01%
Dow Jones
44,728.35
-0.12%
Brent Oil
73.70
2.52%
Bitcoin
95,165.47
-0.73%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Aquestive Therapeutics Inc (AQST) Quote

Aquestive Therapeutics Inc

Aquestive Therapeutics Inc (AQST)

NASDAQ
4.515
-0.295
( -6.13% )
Updated: 12:20:00
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
4.515
Bid
4.51
Ask
4.52
Volume
1,002,374
4.505 Day's Range 4.7999
1.84 52 Week Range 6.23
Market Cap
411.67M
Previous Close
4.81
Open
4.78
Last Trade
1
@
4.5113
Last Trade Time
12:20:28
Financial Volume
$ 4,652,873
VWAP
4.6419
Average Volume (3m)
1,429,727
Shares Outstanding
91,178,193
Dividend Yield
-
PE Ratio
-53.53
Earnings Per Share (EPS)
-0.09
Revenue
50.58M
Net Profit
-7.87M

About Aquestive Therapeutics Inc

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the t... Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.aquestive.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Aquestive Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AQST. The last closing price for Aquestive Therapeutics was $4.81. Over the last year, Aquestive Therapeutics shares have traded in a share price range of $ 1.84 to $ 6.23.

Aquestive Therapeutics currently has 91,178,193 shares outstanding. The market capitalization of Aquestive Therapeutics is $438.57 million. Aquestive Therapeutics has a price to earnings ratio (PE ratio) of -53.53.

Ask ADVFN Intelligence (AI)

AQST Latest News

More News

Form 8-K - Current report

December 02 2024
Edgar (US Regulatory)

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult clinical trials are necessary prior to NDA submission Commenced pediatric trial in the U.S...

December 02 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

November 27 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WAQRREN, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful...

November 12 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

November 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 04 2024
Edgar (US Regulatory)

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Anaphylm™ (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam...

November 04 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.295-6.133056133064.815.2854.4614794054.93545551CS
4-0.485-9.755.594.3616232714.84359768CS
12-0.175-3.731343283584.695.84.3614297274.97067226CS
261.56553.05084745762.955.82.2413540204.1372694CS
522.04582.79352226722.476.231.8415992203.97666923CS
156-0.885-16.38888888895.46.250.6188682203.13180895CS
260-4.085-47.58.69.4650.6188392703.95874754CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CTNTCheetah Net Supply Chain Service Inc
$ 5.3928
(188.39%)
102.5M
ZJKZJK Industrial Company Ltd
$ 15.60
(146.06%)
16.63M
JANXJanux Therapeutics Inc
$ 62.845
(56.41%)
4.63M
GWAVGreenwave Technology Solutions Inc
$ 0.5515
(51.10%)
310.66M
CRDOCredo Technology Group Holding Ltd
$ 71.63
(49.85%)
10.85M
REVBRevelation Biosciences Inc
$ 0.5502
(-42.08%)
3.04M
OMEXOdyssey Marine Exploration Inc
$ 0.4719
(-36.67%)
3.09M
GELSGelteq Ltd
$ 2.60
(-31.95%)
221.4k
XTKGX3 Holdings Company Ltd
$ 1.1401
(-27.84%)
368.99k
STSSSharps Technology Inc
$ 2.42
(-27.84%)
182.68k
GWAVGreenwave Technology Solutions Inc
$ 0.5515
(51.10%)
310.66M
SMCISuper Micro Computer Inc
$ 41.1164
(-2.10%)
150.29M
CTNTCheetah Net Supply Chain Service Inc
$ 5.3928
(188.39%)
102.5M
CHRSCoherus BioSciences Inc
$ 1.98
(44.53%)
96.01M
CTORCitius Oncology Inc
$ 1.48
(45.10%)
94.19M

AQST Discussion

View Posts
52172 52172 1 month ago
Smart man 
👍️0
52172 52172 2 months ago
Exactly
👍️0
52172 52172 2 months ago
No brainer!
👍️0
Sierra20 Sierra20 2 months ago
May breakout soon. Adding and building large position. I like their drugs.
👍️0
TechandBio TechandBio 2 months ago
Building a position here.

$AQST
👍️0
Sierra20 Sierra20 3 months ago
Seeing how fast Neffy maker moved AQST will make the same move.
👍️0
Sierra20 Sierra20 4 months ago
NEFFY is approved. Bad news for AQST very behind
👍️0
Sierra20 Sierra20 4 months ago
Selloff coming
👍️0
52172 52172 4 months ago
Not true
👍️0
Sierra20 Sierra20 5 months ago
Nothing. No updates on Libervant after approval. Now Anaphylm won’t be available for 2 more years.
👍️0
52172 52172 5 months ago
Keep dropping were not done buying!
👍️0
52172 52172 5 months ago
Huge buy opp!
👍️0
Sierra20 Sierra20 6 months ago
It’s heading back to $2. Stop the bleeding please! drug approved but not ready to sell wtf is that? Next earnings will be brutal.
👍️0
PonkenPlonken PonkenPlonken 7 months ago
added. Great science and beautiful chart.
Offerings became bullish.. dont you know?
👍️0
52172 52172 7 months ago
Is a bargain
👍️0
Monksdream Monksdream 7 months ago
AQST under $5

👍️0
52172 52172 8 months ago
Big turn around imminent
👍️0
52172 52172 8 months ago
Yessir absolutely
👍️0
Monksdream Monksdream 8 months ago
In other words you’re confident about this one from the clinical stage drug discovery sector
👍️0
52172 52172 8 months ago
Not for long
👍️0
Monksdream Monksdream 8 months ago
AQST under $5
👍️0
glenn1919 glenn1919 9 months ago
AQST................................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 months ago
AQST new 52 week hi
👍️0
glenn1919 glenn1919 9 months ago
AQST...........................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
I HATE YOU NOW..LOL
👍️0
Monksdream Monksdream 9 months ago
AQST new 52 week high
👍️0
glenn1919 glenn1919 9 months ago
AQST.....................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
52172 52172 9 months ago
Headed much higher!
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AQST..EXIT...MASSIVE PLAY
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AQST...BREAKING 4 BUCKS...BEAST
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AQST...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AQST...MONSTER
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AQST monster bio by the master trend
👍️0
glenn1919 glenn1919 9 months ago
AQST.......................................https://stockcharts.com/h-sc/ui?s=AQST&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 9 months ago
AQST new 52 week high
👍️0
TrendTrade2016 TrendTrade2016 9 months ago
AQST...NEXT BIO WEEKLY BEAST
👍️0
52172 52172 9 months ago
Just the beginning
👍️0
Monksdream Monksdream 10 months ago
AQST new 52 week high
👍️0
Sierra20 Sierra20 11 months ago
Offering coming probably soon.
👍️0
Monksdream Monksdream 11 months ago
AQST new 52 week high
👍️0
shankapotamus shankapotamus 2 years ago
Initiating this one. Fantastic turnaround by company leadership. Look at the ER from last night and see for yourself.
👍️0
trendzone trendzone 2 years ago
Toxic slobs is more like it.
👍️0
crudeoil24 crudeoil24 2 years ago
On going S-3 shelf placement!

AQST
👍️0
crudeoil24 crudeoil24 2 years ago
Aquestive Therapeutics Announces EPIPHAST II Trial Data For AQST-109; Says 'AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen Tmax of 22.5 minutes'
7:05 am ET September 27, 2022 (Benzinga) Print
AQST-109 median time to maximum concentration (Tmax) of 12 minutes was faster than EpiPen® Tmax of 22.5 minutes
AQST-109 repeat dosing provided significantly higher drug plasma concentrations with a Tmax of 8 minutes after administration
Changes in systolic blood pressure and heart rate were similar after a single dose of AQST-109 when compared to a single dose of EpiPen
End-of-Phase 2 meeting with FDA scheduled for fourth quarter 2022 and remaining clinical studies will commence thereafter
Company hosts conference call at 8:00 am ET on September 27, 2022
👍️0
The Night Stalker The Night Stalker 2 years ago
https://www.stockscores.com/chart.asp?TickerSymbol=aqst%20&TimeRange=1825&Interval=m&Volume=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 2 years ago
me=1&ChartType=CandleStick&Stockscores=1&ChartWidth=1100&ChartHeight=480&LogScale=None&Band=None&avgType1=SMA&movAvg1=50&avgType2=SMA&movAvg2=200&Indicator1=AccDist&Indicator2=CMF&Indicator3=StochRSI&Indicator4=MACD&endDate=&CompareWith=&entryPrice=&stopLossPrice=&candles=redgreen
👍️0
The Night Stalker The Night Stalker 2 years ago
nice
👍️0
The Night Stalker The Night Stalker 2 years ago
like this
👍️0
The Night Stalker The Night Stalker 2 years ago
strange POS
👍️0
The Night Stalker The Night Stalker 2 years ago
strange POS
👍️0

Your Recent History

NASDAQ
AQST
Aquestive Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved